Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Sleep Disorders Channel is supported through educational grants from Alkermes and Takeda.

VJNeurology is an independent medical education platform. Channel supporters have no influence over the production of content.

Share this video  

EAN 2021 | Alpha-synuclein aggregation in the olfactory mucosa of patients with isolated RBD vs. PD

Ambra Stefani, MD, Medical University of Innsbruck, Austria, shares the findings of a study aiming to explore real-time quaking-induced conversion (RT-QuIC) detection of α-synuclein aggregates in the olfactory mucosa of a large cohort of subjects with isolated REM sleep behaviour disorder (RBD), compared to patients with Parkinson’s disease and healthy controls. Isolated RBD is regarded as an early stage α-synucleinopathy and detection of pathological α-synuclein in peripheral tissues may identify patients progressing to neurodegenerative disease. Nasal swabs were used to obtain a sample of the olfactory mucosa, which is a minimally invasive process and can be used to detect for pathological alpha-synuclein. The olfactory mucosa was α-synuclein RT-QuIC positive in 44.4% of isolated RBD patients compared to 46.3% in the Parkinson’s disease arm and 10.2% of matched controls. While overall study sensitivity was moderate, the results obtained from this study suggest nasal swabbing may be a useful tool to recognize patients in an early-stage of α-synuclein related neurodegeneration, and may help to select subjects for clinical trials of interventions targeting α-synuclein pathologic conversion and spread. This interview took place during the European Academy of Neurology 2021 congress.